Leqembi终于“起飞”？百健(BIIB.US)Q1业绩打脸悲观预期，阿尔茨海默病药销售暴增74%

智通财经04-29

智通财经APP获悉，制药商百健(BIIB.US)周三发布第一季度财报，数据显示，Q1营收增长2%，至25亿美元;调整后每股收益为3.57美元，同比增长18%，营收及利润双双超出市场平均预期。市场备受关注的阿尔茨海默病药物Leqembi的销售增长及成本削减措施一定程度上抵消了公司多发性硬化症(MS)业务板块所面临的压力。由于近期并购交易产生相关费用，百健下调了全年盈利预期。调整后每股收益预计在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2631519083?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-29 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631519083","market":"sh","top_or_hot":-1,"title":"Leqembi终于“起飞”？百健(BIIB.US)Q1业绩打脸悲观预期，阿尔茨海默病药销售暴增74%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，制药商百健(BIIB.US)周三发布第一季度财报，数据显示，Q1营收增长2%，至25亿美元;调整后每股收益为3.57美元，同比增长18%，营收及利润双双超出市场平均预期。市场备受关注的阿尔茨海默病药物Leqembi的销售增长及成本削减措施一定程度上抵消了公司多发性硬化症(MS)业务板块所面临的压力。由于近期并购交易产生相关费用，百健下调了全年盈利预期。调整后每股收益预计在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436509.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leqembi终于“起飞”？百健(BIIB.US)Q1业绩打脸悲观预期，阿尔茨海默病药销售暴增74%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeqembi终于“起飞”？百健(BIIB.US)Q1业绩打脸悲观预期，阿尔茨海默病药销售暴增74%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 20:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1436509.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，制药商百健(BIIB.US)周三发布第一季度财报，数据显示，Q1营收增长2%，至25亿美元;调整后每股收益为3.57美元，同比增长18%，营收及利润双双超出市场平均预期。市场备受关注的阿尔茨海默病药物Leqembi的销售增长及成本削减措施一定程度上抵消了公司多发性硬化症(MS)业务板块所面临的压力。由于近期并购交易产生相关费用，百健下调了全年盈利预期。调整后每股收益预计在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436509.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z9Z06.USD","symbol_name":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1436509.html","article_id":"2631519083","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631519083","pubTimestamp":1777465082,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"由于近期并购交易产生相关费用，百健下调了全年盈利预期。Leqembi于2023年获批用于治疗阿尔茨海默病，一季度实现销售额1.68亿美元，同比大增74%。若百健能获得美国监管批准，推出更方便居家使用的Leqembi皮下注射新剂型用于阿尔茨海默病患者初始治疗，其销售有望进一步提速。上月，百健同意收购Apellis，从而扩大其在免疫学和罕见病领域的疗法布局。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4533":"AQR资本管理(全球第二大对冲基金)","BIIB":"渤健公司","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"Leqembi finally \"takes off\"? Biogen (BIIB.US) Q1 results slap pessimistic expectations, Alzheimer's drug sales soar 74%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"智通财经APP获悉，制药商百健(BIIB.US)周三发布第一季度财报，数据显示，Q1营收增长2%，至25亿美元;调整后每股收益为3.57美元，同比增长18%，营收及利润双双超出市场平均预期。市场备受关注的阿尔茨海默病药物Leqembi的销售增长及成本削减措施一定程度上抵消了公司多发性硬化症(MS)业务板块所面临的压力。由于近期并购交易产生相关费用，百健下调了全年盈利预期。调整后每股收益预计在14.25美元至15.25美元之间，此前预期为15.25美元至16.25美元。更新后的业绩指引包含一笔与近期达成的交易相关的费用，该交易旨在获得在中国市场销售felzartamab的权利，该药物正在研发用于治疗罕见免疫疾病。新的指引未计入百健最近以56亿美元收购Apellis Pharmaceuticals的财务影响，该收购预计将于第二季度完成。阿尔茨海默病药物抵消MS业务下滑此前，市场担忧百健如何对冲其多发性硬化症药物收入下滑的影响，该板块约占公司产品收入的一半，但正面临仿制药竞争。此次业绩对投资者而言是一个积极信号。财报发布后，百健股价在美国盘前交易时段一度上涨超4%，截至发稿，该股涨1.8%。Leqembi于2023年获批用于治疗阿尔茨海默病，一季度实现销售额1.68亿美元，同比大增74%。该药获批初期放量缓慢，主要受制于医疗体系中的物流障碍以及礼来(LLY.US)同类产品的竞争。这款由百健与日本生物科技公司卫材(Eisai)合作销售的药物，终于开始步入增长轨道。若百健能获得美国监管批准，推出更方便居家使用的Leqembi皮下注射新剂型用于阿尔茨海默病患者初始治疗，其销售有望进一步提速。美国食品药品监督管理局(FDA)预计将于下月就该剂型作出审批决定。成本节约与交易布局百健维持全年营收指引，预计因多发性硬化症药物销售下滑，2026年全年营收将较2025年出现中个位数百分比的下滑。在首席执行官Christopher Viehbacher的领导下，百健已实施裁员并剔除部分管线项目以节省开支。同时，公司也在积极达成交易，拓展特定疾病领域的治疗组合。上月，百健同意收购Apellis，从而扩大其在免疫学和罕见病领域的疗法布局。这是百健有史以来规模最大的收购之一。治疗弗里德赖希共济失调(Friedreich’s ataxia)这一罕见病的药物Skyclarys一季度实现销售额1.51亿美元，超出分析师预期。用于治疗脊髓性肌萎缩症(SMA)的药物Spinraza销售额为3.74亿美元，略低于预期。上月，美国监管机构批准了该药的高剂量版本——该版本用于治疗这一罕见肌肉疾病，为百健在与诺华(NVS.US)基因疗法的竞争中提供了助力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631519083","isCrawlerRequest":true}